<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00709592</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-11561</org_study_id>
    <secondary_id>NCI-2011-01698</secondary_id>
    <nct_id>NCT00709592</nct_id>
  </id_info>
  <brief_title>Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT</brief_title>
  <official_title>Reduced Intensity Myeloablative Total Body Irradiation and Thymoglobulin Followed by Allogeneic Peripheral Blood Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      One of two different doses of thymoglobulin will allow bone marrow engraftment with minimal
      Graft-versus-Host Disease and allow adequate immune response to allow the transplanted stem
      cells to replace the tumor cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized phase II trial studies how well giving low dose total-body irradiation (TBI)
      with anti-thymocyte globulin followed by donor peripheral blood stem cell transplant (PBSCT)
      works in treating patients with hematologic malignancies. Giving reduced intensity total-body
      irradiation and anti-thymocyte globulin before a donor peripheral blood stem cell transplant
      helps stop the growth of cancer cells. It may also stop the patient's immune system from
      rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into
      the patient they may help the patient's bone marrow make stem cells, red blood cells, white
      blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune
      response against the body's normal cells. Giving total-body irradiation together with
      antithymocyte globulin before transplant may stop this from happening.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 21, 2008</start_date>
  <completion_date type="Actual">June 28, 2017</completion_date>
  <primary_completion_date type="Actual">February 15, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Comparison of Functional Immune Reconstitution at 6-9 Months Following Transplant as Measured by Antibody Response to Vaccination With Inactivated Hepatitis A or B Vaccine.</measure>
    <time_frame>Up to 9 months following transplant</time_frame>
    <description>A positive test result will indicate immune reconstitution, while a negative test results will indicate lack of immune reconstitution. Participants not done (ND) will be counted with the negative (Neg).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Engraftment of Donor Hematopoietic Stem Cells, as Measured by Neutrophil and Platelet Counts</measure>
    <time_frame>12 day median</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>2-year survival rate (%)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Related Mortality</measure>
    <time_frame>Day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>2 year relapse rate (%)</time_frame>
    <description>Patients with different disease relapses was determined according to current clinical standards based on the disease. For example, AML or MDS relapse is determined by a bone marrow biopsy. Multiple myeloma relapse requires a number of labs and/or biopsy to diagnose such as SPEP, UPEP, immunofixation, serum and urine light chains. In lymphoma disease is followed using CT and/or PET scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Lymphocyte Infusion</measure>
    <time_frame>2 year rate of DLI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Graft-Versus-Host Disease (GVHD)</measure>
    <time_frame>2 year rate (%)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Graft-Versus-Host Disease (GVHD)</measure>
    <time_frame>2 year GVHD rate</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Leukemia</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>ATG 1.7 mg/kg, TBI, transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Rabbit-ATG;Thymoglobulin,Genzyme) ATG 5.1 mg/kg in three divided doses (1.7 mg/kg/d) given over three days (day -9 to -7) followed by 450 cGy TBI and tacrolimus plus MMF GVHD prophylaxis. Patients receive lower dose anti-thymocyte globulin IV on days -9 to -7. Patients undergo total-body radiation (TBI) twice daily (BID) on day -1 and once daily (QD) on day 0. Patients then undergo peripheral blood stem cells or bone marrow transplant on day 0. GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: patients receive tacrolimus orally (PO) on days -2 to 90-120 with taper for 2 months, and mycophenolate mofetil (MMF) PO BID on days 0-30.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATG 2.5 mg/kg/d, TBI, transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Rabbit-ATG;Thymoglobulin,Genzyme) ATG 7.5 mg/kg in three divided doses (2.5 mg/kg/d) given over three days (day -9 to -7) followed by 450 cGy TBI and tacrolimus plus MMF GVHD prophylaxis. Patients receive higher dose anti-thymocyte globulin intravenously (IV) on days -9 to -7. Patients undergo total-body radiation (TBI) twice daily (BID) on day -1 and once daily (QD) on day 0. Patients then undergo peripheral blood stem cells or bone marrow transplant on day 0. GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: patients receive tacrolimus orally (PO) on days -2 to 90-120 with taper for 2 months, and mycophenolate mofetil (MMF) PO BID on days 0-30.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>Patients eligible for participation in this study will be randomized between receiving rabbit ATG for 3 days. Thymoglobulin will be administered according to VCU BMT standard of care starting day -9 and continued daily through day -7.</description>
    <arm_group_label>ATG 1.7 mg/kg, TBI, transplant</arm_group_label>
    <arm_group_label>ATG 2.5 mg/kg/d, TBI, transplant</arm_group_label>
    <other_name>anti-thymocyte globulin (rabbit)</other_name>
    <other_name>ATG</other_name>
    <other_name>Genzyme</other_name>
    <other_name>anti-thymocyte globulin</other_name>
    <other_name>Rabbit</other_name>
    <other_name>Rabbit-ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>ATG 1.7 mg/kg, TBI, transplant</arm_group_label>
    <arm_group_label>ATG 2.5 mg/kg/d, TBI, transplant</arm_group_label>
    <other_name>Whole-Body Irradiation</other_name>
    <other_name>Total Body Irradiation [TBI]</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic PBSCT or BMT</intervention_name>
    <description>Undergo allogeneic PBSCT or BMT</description>
    <arm_group_label>ATG 1.7 mg/kg, TBI, transplant</arm_group_label>
    <arm_group_label>ATG 2.5 mg/kg/d, TBI, transplant</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Blood Stem Cell Transplantation [Allogenic PBSCT]</other_name>
    <other_name>Allogeneic Bone Marrow Transplantation [BMT]</other_name>
    <other_name>Allogeneic BMT</other_name>
    <other_name>Allogeneic Hematopoietic Stem Cell Transplantation</other_name>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given PO</description>
    <arm_group_label>ATG 1.7 mg/kg, TBI, transplant</arm_group_label>
    <arm_group_label>ATG 2.5 mg/kg/d, TBI, transplant</arm_group_label>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given PO</description>
    <arm_group_label>ATG 1.7 mg/kg, TBI, transplant</arm_group_label>
    <arm_group_label>ATG 2.5 mg/kg/d, TBI, transplant</arm_group_label>
    <other_name>CellCept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hematological malignancies for which allogeneic stem cell
             transplantation indicated including non-Hodgkin lymphoma (NHL), multiple myeloma (MM),
             acute myeloid leukemia (AML), Hodgkin lymphoma (HD), chronic lymphocytic leukemia
             (CLL), chronic myelogenous leukemia (CML), and myelodysplastic syndrome (MDS)

          -  Patients with HLA compatible related or unrelated stem cell donor, willing and able to
             serve as an allogenic HSC donor. Unrelated donors have to be matched at HLA-A, B, C
             and DRB1 loci. A single locus mismatch will be tolerated in the event a more closely
             matched donor is not available.

          -  Patients age &gt;/=40 to &lt;/=70 with an ECOG performance status &lt; 2

          -  Patients between 18 and 40 years of age will be eligible only if they have
             co-morbidities precluding conventional allogeneic transplantation with full intensity
             myeloablative conditioning

          -  Adequate cardiac, pulmonary, renal and hepatic function for transplant

          -  Negative serology for HIV

          -  Negative serum pregnancy test

          -  Patients who have received therapeutic radiation to a localized field will be
             eligible, provided critical structure tolerance doses have not been exceeded

          -  Patients who have had prior myeloablative autologous transplant will be eligible

        Exclusion Criteria:

          -  Evidence of uncontrolled viral, fungal, bacterial infection

          -  Evidence of active meningeal or CNS disease

          -  Prior therapy with rabbit ATG, prior treatment with equine ATG is allowed if more than
             3 months ago

          -  Breast feeding mothers are excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amir Toor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massey Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University/Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.massey.vcu.edu/</url>
    <description>VCU Massey Cancer Center</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2008</study_first_submitted>
  <study_first_submitted_qc>July 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2008</study_first_posted>
  <results_first_submitted>February 1, 2015</results_first_submitted>
  <results_first_submitted_qc>February 1, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 12, 2015</results_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>total body irradiation</keyword>
  <keyword>Allogeneic Peripheral Blood Stem Cell Transplantation</keyword>
  <keyword>thymoglobulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Consecutive patients enrolled have recurrent or high-risk hematologic malignancy, adequate end-organ function and performance status. Patient required to have 7/8 or 8/8 mismatched related donor (MRD) or unrelated donor (URD), with high-resolution typing performed for HLA-A, -B, -C, and -DRB1.</recruitment_details>
      <pre_assignment_details>Randomized to rabbit ATG (Thymoglobulin; Genzyme, Cambridge, MA), 2.5 or 1.7 mg/kg adjusted ideal body weight/day, followed by TBI to a total dose of 4.5 Gy. Methylprednisolone 2 mg/kg given pre-medication for ATG. GVHD prophylaxis was tacrolimus starting at approximately 12 weeks post transplantation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>A:Thymoglobulin: 1.7 mg/kg/Day</title>
          <description>1.7 mg/kg/d thymoglobulin IV d-9 to -7</description>
        </group>
        <group group_id="P2">
          <title>B:Thymoglobulin: 2.5 mg/kg/Day</title>
          <description>2.5 mg/kg/d thymoglobulin IV d-9 to d-7</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unable to proceed to transplant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects able to proceed to transplant.</population>
      <group_list>
        <group group_id="B1">
          <title>A:Thymoglobulin: 1.7 mg/kg/Day</title>
          <description>1.7 mg/kg/d thymoglobulin IV d-9 to -7</description>
        </group>
        <group group_id="B2">
          <title>B:Thymoglobulin: 2.5 mg/kg/Day</title>
          <description>2.5 mg/kg/d thymoglobulin IV d-9 to d-7</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="44" upper_limit="69"/>
                    <measurement group_id="B2" value="57" lower_limit="40" upper_limit="68"/>
                    <measurement group_id="B3" value="57" lower_limit="40" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Comparison of Functional Immune Reconstitution at 6-9 Months Following Transplant as Measured by Antibody Response to Vaccination With Inactivated Hepatitis A or B Vaccine.</title>
        <description>A positive test result will indicate immune reconstitution, while a negative test results will indicate lack of immune reconstitution. Participants not done (ND) will be counted with the negative (Neg).</description>
        <time_frame>Up to 9 months following transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A:Thymoglobulin: 1.7 mg/kg/Day</title>
            <description>1.7 mg/kg/d thymoglobulin IV d-9 to -7</description>
          </group>
          <group group_id="O2">
            <title>B:Thymoglobulin: 2.5 mg/kg/Day</title>
            <description>2.5 mg/kg/d thymoglobulin IV d-9 to d-7</description>
          </group>
        </group_list>
        <measure>
          <title>The Comparison of Functional Immune Reconstitution at 6-9 Months Following Transplant as Measured by Antibody Response to Vaccination With Inactivated Hepatitis A or B Vaccine.</title>
          <description>A positive test result will indicate immune reconstitution, while a negative test results will indicate lack of immune reconstitution. Participants not done (ND) will be counted with the negative (Neg).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative/Not Done</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Engraftment of Donor Hematopoietic Stem Cells, as Measured by Neutrophil and Platelet Counts</title>
        <time_frame>12 day median</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival</title>
        <time_frame>2-year survival rate (%)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A:Thymoglobulin: 1.7 mg/kg/Day</title>
            <description>1.7 mg/kg/d thymoglobulin IV d-9 to -7</description>
          </group>
          <group group_id="O2">
            <title>B:Thymoglobulin: 2.5 mg/kg/Day</title>
            <description>2.5 mg/kg/d thymoglobulin IV d-9 to d-7</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <units>percentage of patient surviving</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3"/>
                    <measurement group_id="O2" value="62.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Related Mortality</title>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A:Thymoglobulin: 1.7 mg/kg/Day</title>
            <description>1.7 mg/kg/d thymoglobulin IV d-9 to -7</description>
          </group>
          <group group_id="O2">
            <title>B:Thymoglobulin: 2.5 mg/kg/Day</title>
            <description>2.5 mg/kg/d thymoglobulin IV d-9 to d-7</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Related Mortality</title>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event-free Survival</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A:Thymoglobulin: 1.7 mg/kg/Day</title>
            <description>1.7 mg/kg/d thymoglobulin IV d-9 to -7</description>
          </group>
          <group group_id="O2">
            <title>B:Thymoglobulin: 2.5 mg/kg/Day</title>
            <description>2.5 mg/kg/d thymoglobulin IV d-9 to d-7</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.2"/>
                    <measurement group_id="O2" value="44.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapse</title>
        <description>Patients with different disease relapses was determined according to current clinical standards based on the disease. For example, AML or MDS relapse is determined by a bone marrow biopsy. Multiple myeloma relapse requires a number of labs and/or biopsy to diagnose such as SPEP, UPEP, immunofixation, serum and urine light chains. In lymphoma disease is followed using CT and/or PET scans.</description>
        <time_frame>2 year relapse rate (%)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A:Thymoglobulin: 1.7 mg/kg/Day</title>
            <description>1.7 mg/kg/d thymoglobulin IV d-9 to -7</description>
          </group>
          <group group_id="O2">
            <title>B:Thymoglobulin: 2.5 mg/kg/Day</title>
            <description>2.5 mg/kg/d thymoglobulin IV d-9 to d-7</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse</title>
          <description>Patients with different disease relapses was determined according to current clinical standards based on the disease. For example, AML or MDS relapse is determined by a bone marrow biopsy. Multiple myeloma relapse requires a number of labs and/or biopsy to diagnose such as SPEP, UPEP, immunofixation, serum and urine light chains. In lymphoma disease is followed using CT and/or PET scans.</description>
          <units>Percent patients relapsing</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Donor Lymphocyte Infusion</title>
        <time_frame>2 year rate of DLI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A:Thymoglobulin: 1.7 mg/kg/Day</title>
            <description>1.7 mg/kg/d thymoglobulin IV d-9 to -7</description>
          </group>
          <group group_id="O2">
            <title>B:Thymoglobulin: 2.5 mg/kg/Day</title>
            <description>2.5 mg/kg/d thymoglobulin IV d-9 to d-7</description>
          </group>
        </group_list>
        <measure>
          <title>Donor Lymphocyte Infusion</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9"/>
                    <measurement group_id="O2" value="45.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Graft-Versus-Host Disease (GVHD)</title>
        <time_frame>2 year rate (%)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A:Thymoglobulin: 1.7 mg/kg/Day</title>
            <description>1.7 mg/kg/d thymoglobulin IV d-9 to -7</description>
          </group>
          <group group_id="O2">
            <title>B:Thymoglobulin: 2.5 mg/kg/Day</title>
            <description>2.5 mg/kg/d thymoglobulin IV d-9 to d-7</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Graft-Versus-Host Disease (GVHD)</title>
          <units>percentage of participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2"/>
                    <measurement group_id="O2" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Graft-Versus-Host Disease (GVHD)</title>
        <time_frame>2 year GVHD rate</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A:Thymoglobulin: 1.7 mg/kg/Day</title>
            <description>1.7 mg/kg/d thymoglobulin IV d-9 to -7</description>
          </group>
          <group group_id="O2">
            <title>B:Thymoglobulin: 2.5 mg/kg/Day</title>
            <description>2.5 mg/kg/d thymoglobulin IV d-9 to d-7</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic Graft-Versus-Host Disease (GVHD)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8"/>
                    <measurement group_id="O2" value="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All events collected from first patient accrual up to day 180 or relapse for each subject on each arm.</time_frame>
      <desc>Still collecting SAEs, subjects on trial until death.</desc>
      <group_list>
        <group group_id="E1">
          <title>A:Thymoglobulin: 1.7 mg/kg/Day</title>
          <description>1.7 mg/kg/d thymoglobulin IV d-9 to -7</description>
        </group>
        <group group_id="E2">
          <title>B:Thymoglobulin: 2.5 mg/kg/Day</title>
          <description>2.5 mg/kg/d thymoglobulin IV d-9 to d-7</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE version 3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac dysrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic</sub_title>
                <description>liver</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Intra-abdominal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>vomiting</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever with out bacteremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Fever with Bacteremia +/- abscess</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <description>brain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>CNS toxicity</sub_title>
                <description>brain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Brain abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhagic cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE version 3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 neutropenia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="19"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Lymphopenia post conditioning</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="19"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="19"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Post transplant neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteremia/Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>UTI</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amir A Toor, MD</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>804-828-4360</phone>
      <email>atoor@mcvh-vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

